Focus
Cancer Technologies
- Focus issue:
- July 2012 Volume 30, No 7
Increased understanding of the molecular defects associated with malignancies is opening up new opportunities in diagnosis and therapy. This focus issue of Nature Biotechnology highlights a selection of new technologies that promise to facilitate the development of more effective cancer treatments.
Editorial
Focus on Cancer Technologies
Recasting cancer trials - p567
doi:10.1038/nbt.2315
Wanted: faster, more effective ways of testing experimental cancer drugs for both single-agent and combination treatments.
Abstract - | Full Text - Recasting cancer trials | PDF (125 KB) - Recasting cancer trials
News Features
Focus on Cancer Technologies
Beyond counting tumor cells - pp578 - 580
Jim Kling
doi:10.1038/nbt.2295
Since the discovery of circulating tumor cells in 1869, researchers have been able to do little else beyond count them. This is about to change, as advanced technologies for harvesting and analyzing rare cells from blood are opening the window for characterization. Jim Kling reports.
Abstract - | Full Text - Beyond counting tumor cells | PDF (188 KB) - Beyond counting tumor cells
Focus on Cancer Technologies
Reading cancer's blueprint - pp581 - 584
Michael Eisenstein
doi:10.1038/nbt.2292
Coinciding with last month's annual meeting of the American Society of Clinical Oncology, at least one business launched with a plan to use genetic information from patient tumors to help guide treatment. Michael Eisenstein investigates.
Abstract - | Full Text - Reading cancer's blueprint | PDF (196 KB) - Reading cancer's blueprint
Commentaries
Focus on Cancer Technologies
Incorporating biomarkers into clinical trial designs: points to consider - pp596 - 599
Edward Bradley
doi:10.1038/nbt.2296
In an environment where the regulatory and reimbursement authorities continue to raise the bar for new oncology therapies, how are sponsors adapting clinical trial designs?
Abstract - | Full Text - Incorporating biomarkers into clinical trial designs: points to consider | PDF (360 KB) - Incorporating biomarkers into clinical trial designs: points to consider
Focus on Cancer Technologies
The Multiple Myeloma Research Foundation's evolving focus on drug R&D - pp600 - 603
Kathy Giusti
doi:10.1038/nbt.2297
The Multiple Myeloma Research Foundation (MMRF) has developed innovative, collaborative business models to reshape the R&D enterprise with the single-minded focus of accelerating the development of new treatments for patients to extend their lives and lead to a cure.
Abstract - | Full Text - The Multiple Myeloma Research Foundation's evolving focus on drug R&D | PDF (190 KB) - The Multiple Myeloma Research Foundation's evolving focus on drug R&D
Features
Focus on Cancer Technologies
The challenges posed by cancer heterogeneity - pp604 - 610
Sangeeta Bhatia, John V Frangioni, Robert M Hoffman, A John Iafrate & Kornelia Polyak
doi:10.1038/nbt.2294
A panel of five experts discuss the implications of cancer heterogeneity for diagnostics and therapy.
Abstract - | Full Text - The challenges posed by cancer heterogeneity | PDF (334 KB) - The challenges posed by cancer heterogeneity
Focus on Cancer Technologies
T-cell therapy at the threshold - pp611 - 614
Carl June, Steven A Rosenberg, Michel Sadelain & Jeffrey S Weber
doi:10.1038/nbt.2305
Despite impressive clinical activity in B-cell lymphoma and melanoma, questions remain about the immunobiology of adoptive T-cell therapies.
Abstract - | Full Text - T-cell therapy at the threshold | PDF (275 KB) - T-cell therapy at the threshold
Focus on Cancer Technologies
Recent patent applications in cancer biomarkers - p619
doi:10.1038/nbt.2308
Full Text - Recent patent applications in cancer biomarkers | PDF (47 KB) - Recent patent applications in cancer biomarkers
News and Views
Focus on Cancer Technologies
ABSOLUTE cancer genomics - pp620 - 621
Peter Van Loo & Peter J Campbell
doi:10.1038/nbt.2293
Calculating absolute copy numbers in cancer genome sequences identifies disease-associated genes and provides insights into tumor evolution and heterogeneity.
Full Text - ABSOLUTE cancer genomics | PDF (212 KB) - ABSOLUTE cancer genomics
Focus on Cancer Technologies
New lysine methyltransferase drug targets in cancer - pp622 - 623
Tobias Wagner & Manfred Jung
doi:10.1038/nbt.2300
Recent preclinical studies suggest that inhibitors of histone methyltransferases represent promising drug candidates for cancer therapy.
Full Text - New lysine methyltransferase drug targets in cancer | PDF (263 KB) - New lysine methyltransferase drug targets in cancer
Research
Perspective
Focus on Cancer Technologies
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma - pp631 - 637
Peter D Senter & Eric L Sievers
doi:10.1038/nbt.2289
Abstract - | Full Text - The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma | PDF (4,637 KB) - The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Reviews
Focus on Cancer Technologies
From single cells to deep phenotypes in cancer - pp639 - 647
Sean C Bendall & Garry P Nolan
doi:10.1038/nbt.2283
Abstract - | Full Text - From single cells to deep phenotypes in cancer | PDF (1,162 KB) - From single cells to deep phenotypes in cancer
Focus on Cancer Technologies
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu - pp648 - 657
Mallika Singh & Napoleone Ferrara
doi:10.1038/nbt.2286
Abstract - | Full Text - Modeling and predicting clinical efficacy for drugs targeting the tumor milieu | PDF (1,042 KB) - Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
Focus on Cancer Technologies
Oncolytic virotherapy - pp658 - 670
Stephen J Russell, Kah-Whye Peng & John C Bell
doi:10.1038/nbt.2287
Abstract - | Full Text - Oncolytic virotherapy | PDF (1,751 KB) - Oncolytic virotherapy
Focus on Cancer Technologies
Therapeutic targets in cancer cell metabolism and autophagy - pp671 - 678
Heesun Cheong, Chao Lu, Tullia Lindsten & Craig B Thompson
doi:10.1038/nbt.2285
Abstract - | Full Text - Therapeutic targets in cancer cell metabolism and autophagy | PDF (1,155 KB) - Therapeutic targets in cancer cell metabolism and autophagy
Focus on Cancer Technologies
Combinatorial drug therapy for cancer in the post-genomic era - pp679 - 692
Bissan Al-Lazikani, Udai Banerji & Paul Workman
doi:10.1038/nbt.2284
Abstract - | Full Text - Combinatorial drug therapy for cancer in the post-genomic era | PDF (2,257 KB) - Combinatorial drug therapy for cancer in the post-genomic era
© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.
